Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Aart van der Meijden"'
Autor:
Hessel Van der Weide, Marian T. Ten Kate, Denise M. C. Vermeulen-de Jongh, Aart Van der Meijden, Rixt A. Wijma, Stefan A. Boers, Mireille Van Westreenen, John P. Hays, Wil H. F. Goessens, Irma A. J. M. Bakker-Woudenberg
Publikováno v:
Antibiotics, Vol 9, Iss 3, p 109 (2020)
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a “drug of last resort” warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative bacterial infect
Externí odkaz:
https://doaj.org/article/465bf063032a4ca9b1db1abef27c2717
Autor:
Aart van der Meijden, Vincent Aranzana-Climent, Heleen van der Spek, Brenda C M de Winter, William Couet, Joseph Meletiadis, Anouk E Muller, Sanne van den Berg
Publikováno v:
The Journal of antimicrobial chemotherapy, 78(3), 832-839. Oxford University Press
BackgroundAlthough polymyxin B has been in use since the late 1950s, there have been limited studies done to unravel its pharmacokinetics (PK) and pharmacodynamics (PD) index.MethodsWe determined, in neutropenic infected mice, the PK, plasma protein
Autor:
Anouk E. Muller, Merel Raaphorst, Aart van der Meijden, Brenda C. M. de Winter, Joseph Meletiadis, Sanne van den Berg
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Temocillin is used for the treatment of various infections caused by Enterobacterales . The pharmacokinetic (PK)/pharmacodynamic (PD) index that is best correlated with the activity of beta-lactams is the percentage of time that the unbound concentra
Autor:
Jurriaan E. M. de Steenwinkel, Rami Ayoun Alsoud, Hannelore I. Bax, Saskia E. Mudde, Manisha U. Lotlikar, Aart van der Meijden, Anna M. Upton, Ulrika S. H. Simonsson
Publikováno v:
The Journal of infectious diseases, 225(11), 1876-1885. Oxford University Press
Background Given the persistently high global burden of tuberculosis, effective and shorter treatment options are needed. We explored the relationship between relapse and treatment length as well as interregimen differences for 2 novel antituberculos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83548a6b4c01dd3d15020141c91896b1
https://pure.eur.nl/en/publications/df56d81f-b9de-48b0-8768-1143a3afc237
https://pure.eur.nl/en/publications/df56d81f-b9de-48b0-8768-1143a3afc237
Autor:
Matthew D. Zimmerman, Elise D Pieterman, Han Wang, Lina Keutzer, Ulrika S. H. Simonsson, Aart van der Meijden, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel, Sanne van den Berg
Publikováno v:
J Infect Dis
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Background The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. Methods We compared the efficacy of an all oral DR tuberculosis drug regimen consi
Autor:
Mireille van Westreenen, Hessel van der Weide, Stefan A. Boers, Wil H. F. Goessens, Rixt A. Wijma, John P. Hays, Marian T. ten Kate, Denise M. C. Vermeulen-de Jongh, Aart van der Meijden, Irma A. J. M. Bakker-Woudenberg
Publikováno v:
Antibiotics, Vol 9, Iss 3, p 109 (2020)
Antibiotics
Antibiotics-Basel, 9(3):109. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 9
Issue 3
Antibiotics
Antibiotics-Basel, 9(3):109. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 9
Issue 3
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a &ldquo
drug of last resort&rdquo
warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative
drug of last resort&rdquo
warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative
Autor:
Iain J, Abbott, Elke, van Gorp, Aart, van der Meijden, Rixt A, Wijma, Joseph, Meletiadis, Jason A, Roberts, Johan W, Mouton, Anton Y, Peleg
Publikováno v:
Antimicrob Agents Chemother
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undert
Autor:
Iraida Loinaz, Jeffrey A. S. Ritsema, Hessel van der Weide, Wil H. F. Goessens, Yvonne M. te Welscher, Gert Storm, Cornelus F. van Nostrum, Marco Marradi, Irma A. J. M. Bakker-Woudenberg, John P. Hays, Denise M. C. Vermeulen-de Jongh, Marian T. ten Kate, Raquel Gracia, Unai Cossío, Jordi Llop, Aart van der Meijden
Publikováno v:
Antimicrobial Agents and Chemotherapy, 64(9):e00517-20. American Society for Microbiology
Antimicrob Agents Chemother
Antimicrob Agents Chemother
Antimicrobial peptides (AMPs) have seen limited clinical use as antimicrobial agents, largely due to issues relating to toxicity, short biological half-life, and lack of efficacy against Gram-negative bacteria. However, the development of novel AMP-n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a678d0c1a543c068276562cbf7da70ec
https://pure.eur.nl/en/publications/de69b7db-96a2-4f2e-9aa2-19462a0a6028
https://pure.eur.nl/en/publications/de69b7db-96a2-4f2e-9aa2-19462a0a6028
Autor:
Elke van Gorp, Anton Y. Peleg, Johan W. Mouton, Joseph Meletiadis, Rixt A. Wijma, Iain J. Abbott, Aart van der Meijden, Jason A. Roberts
Publikováno v:
Antimicrobial Agents & Chemotherapy, 64(6):e00342-20. American Society for Microbiology
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4736186fe0ce7cb954c7a0a5df606a
https://pure.eur.nl/en/publications/68c517a2-9fc7-4996-9e82-da40d6a1875d
https://pure.eur.nl/en/publications/68c517a2-9fc7-4996-9e82-da40d6a1875d
Autor:
Corné P. de Vogel, Aart van der Meijden, Jurriaan E. M. de Steenwinkel, Irma A. J. M. Bakker-Woudenberg, Annelies Verbon, Hannelore I. Bax
Publikováno v:
Tuberculosis, 105, 80-85. Churchill Livingstone
Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical models assessing anti-tuberculosis drug activity are available, but it is yet unclear which combination of models is most predictive of clinical treatment eff